TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01861743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Analgesia
Description: Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Subjects will be treated with patient controlled narcotic analgesia for pain management.
Study: NCT01626482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
Study: NCT01969773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline instillation
Description: Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
Study: NCT03303313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Subcutaneous (sc) injection of Cemdisiran
Study: NCT02140151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Study: NCT02926443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Neuromuscular Training Program
Description: Neuromuscular and strengthening shoulder exercises in a group setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy Care
Description: One-on-one physiotherapy care in a clinical setting.
Study: NCT03838536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Egg Powder
Description: Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg White Powder
Description: Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
Study: NCT02240212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel sourced locally will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel sourced locally will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel sourced locally will be administered IV
Study: NCT00722969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib + erlotinib
Description: sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
Study: NCT00677664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate (Copaxone)
Description: Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
Study: NCT02021929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a kinase inhibitor indicated for the treatment of:~* Unresectable hepatocellular carcinoma~* Advanced renal cell carcinoma~* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01967862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging
Description: Undergo axial MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo WB MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Undergo fluorine F 18 sodium fluoride PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04756882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 UNT
Description: Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes
Study: NCT02757261

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo laser
Description: Placebo laser (Low-level laser therapy administrated to acupoints)
Study: NCT01650480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELP-COPD action plan
Description: The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
Study: NCT04562350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XatJove Anoia Aplication
Description: All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
Study: NCT00444535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg oral lapatinib (once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg intravenous bevacizumab (every two weeks)
Study: NCT03138213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic pancreaticoduodenectomy
Description: Total laparoscopic pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open pancreaticoduodenectomy
Description: Open pancreaticoduodenectomy
Study: NCT02964481

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: DNA sequencing of protein coding sections of all genes

Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: DNA sequencing of protein coding sections of all genes
Study: NCT03718637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Bioinductive Implant
Description: A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Epicondylectomy
Description: This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Epicondylectomy
Description: This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient both preoperatively and at 6 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient both preoperatively and at 6 months.
Study: NCT01832064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed Chronic Disease Self-Management Program
Description: materials are mailed to participants
Study: NCT02498197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01978132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forearm ischemia and reperfusion
Description: both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: forearm ischemia and reperfusion
Description: both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
Study: NCT00413582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-Controlled IV Analgesia
Description: In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
Study: NCT00762255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study: NCT01774760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-EF5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pretreatment PET/CT-scan (performed two times)
Study: NCT04396808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decipher
Description: The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolaris
Description: The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oncotype Dx Genomic Prostate Score (GPS)
Description: The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (askMUSIC score)
Description: AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
Study: NCT04252690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM® autofit : auto-adjustable compression stocking
Description: The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey).
Study: NCT04396808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (askMUSIC score)
Description: AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
Study: NCT00989482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer kiosk Education
Description: computerized patient education; guidelines for physicians
Study: NCT03729167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
Study: NCT03065855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early removal group
Description: Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal removal group
Description: Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
Study: NCT02069639

Intervention type: OTHER
Intervention: no treatment
Study: NCT01600300

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Tesmac device
Description: Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
Study: NCT04275388

Intervention type: DRUG
Intervention: Xiyanping injection
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,

Intervention type: DRUG
Intervention: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride

Intervention type: DRUG
Intervention: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
Study: NCT02311543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil® patches
Description: TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
Study: NCT03751319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGA
Description: Comprehensive Geriatric Assessment
Study: NCT00999245

Intervention type: OTHER
Group type: OTHER
Intervention: High Demand / Low Infusion
Description: HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.

Intervention type: OTHER
Group type: OTHER
Intervention: PCA Dosing Plan
Description: LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
Study: NCT03870737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TNS
Description: Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
Study: NCT00759174

Intervention type: DRUG
Intervention: No intervention
Description: No intervention occurs in this observational study.
Study: NCT00709735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (matching propranolol) short-acting and long-acting capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching propranolol) short-acting and long-acting capsules
Study: NCT01532011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.
Study: NCT03800186

Intervention type: OTHER
Intervention: Proximal type A
Description: Patients with fracture of proximal type A

Intervention type: OTHER
Intervention: Proximal type B
Description: Patients with fracture of proximal type B

Intervention type: OTHER
Intervention: Proximal type C
Description: Patients with fracture of proximal type C

Intervention type: OTHER
Intervention: femoral shaft
Description: Patients with fracture of femoral shaft

Intervention type: OTHER
Intervention: distal femur
Description: Patients with fracture of distal femur
Study: NCT04861415

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic Body Radiotherapy
Description: Hypofractionated stereotactic radiation treatment.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Radiation
Description: External beam radiation therapy treatment
Study: NCT01938092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00419991

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tigecycline
Description: All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
Study: NCT01294176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipoic Acid
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoic Acid
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
Study: NCT01436513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin reference tablet (fasted)
Description: Premarin reference tablet, single dose, fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin new tablet (fasted)
Description: Premarin new tablet, single dose, fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin reference tablet (fed)
Description: Premarin reference tablet, single dose, fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin new tablet (fed)
Description: Premarin new tablet, single dose, fed conditions